Mirum Pharmaceuticals Inc
MIRM69.710USD
0.000
收盤 11/10, 16:00（美東）報價延遲15分鐘
3.58B總市值
虧損本益比TTM
關於 Mirum Pharmaceuticals Inc 公司
Mirum Pharmaceuticals, Inc. 是一家生物製藥公司。該公司專注於識別、收購、開發和商業化治療衰弱性罕見病和孤兒病的療法。該公司有三種藥物：LIVMARLI（maralixibat）口服溶液（Livmarli）、Cholbam（膽酸）膠囊和 Chenodal（chenodiol）片劑。Livmarli 是一種口服、最低吸收的迴腸膽汁酸轉運蛋白 (IBAT) 抑制劑 (IBATi)，用於治療美國和其他多個國家 Alagille 綜合徵 (ALGS) 患者的膽汁淤積性瘙癢以及美國進行性家族性肝內膽汁淤積 (PFIC) 患者的膽汁淤積性瘙癢。Cholbam 用於治療因單一酶缺乏引起的膽汁酸合成障礙和過氧化物酶體疾病的輔助治療。該公司還在推進其候選產品 volixibat，用於治療患有膽汁淤積性肝病的成年患者。
Mirum Pharmaceuticals Inc簡介
公司代碼MIRM
公司名稱Mirum Pharmaceuticals Inc
上市日期Jul 18, 2019
CEOMr. Christopher (Chris) Peetz
員工數量322
證券類型Ordinary Share
年結日Jul 18
公司地址989 East Hillsdale Boulevard, Suite 300
城市FOSTER CITY
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94404
電話16506674085
網址https://mirumpharma.com/
公司代碼MIRM
上市日期Jul 18, 2019
CEOMr. Christopher (Chris) Peetz
Mirum Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
39.66K
+28.33%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
5.65K
--
Mr. Andrew Mckibben
Mr. Andrew Mckibben
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
39.66K
+28.33%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
業務USD
名稱
營收
佔比
Livmarli
88.16M
68.99%
Bile Acid Medicines
39.63M
31.01%
License and other revenue
0.00
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Livmarli
88.16M
68.99%
Bile Acid Medicines
39.63M
31.01%
License and other revenue
0.00
0.00%
股東統計
更新時間: 10月31日 週五
更新時間: 10月31日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
13.22%
Janus Henderson Investors
10.19%
BlackRock Institutional Trust Company, N.A.
6.04%
BVF Partners L.P.
5.37%
Eventide Asset Management, LLC
5.13%
其他
60.04%
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
13.22%
Janus Henderson Investors
10.19%
BlackRock Institutional Trust Company, N.A.
6.04%
BVF Partners L.P.
5.37%
Eventide Asset Management, LLC
5.13%
其他
60.04%
股東類型
持股股東
佔比
Investment Advisor
34.70%
Investment Advisor/Hedge Fund
32.60%
Hedge Fund
21.58%
Private Equity
13.68%
Research Firm
4.26%
Venture Capital
2.92%
Individual Investor
1.84%
Sovereign Wealth Fund
0.99%
Pension Fund
0.69%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
468
57.20M
111.61%
-6.92M
2025Q2
458
58.36M
116.21%
-4.59M
2025Q1
454
57.59M
116.38%
-4.84M
2024Q4
425
56.60M
115.52%
-10.44M
2024Q3
408
56.58M
118.52%
-12.05M
2024Q2
398
57.22M
121.33%
-10.51M
2024Q1
391
57.27M
121.82%
-5.03M
2023Q4
376
54.05M
116.10%
-4.66M
2023Q3
337
55.34M
123.03%
+4.03M
2023Q2
315
43.67M
117.43%
-6.40M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frazier Life Sciences Management, L.P.
6.80M
13.53%
--
--
Aug 18, 2025
Janus Henderson Investors
5.24M
10.42%
+154.32K
+3.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.10M
6.18%
+88.20K
+2.92%
Jun 30, 2025
BVF Partners L.P.
2.76M
5.5%
-35.18K
-1.26%
Jun 30, 2025
Eventide Asset Management, LLC
2.64M
5.25%
+110.48K
+4.37%
Jun 30, 2025
The Vanguard Group, Inc.
2.56M
5.09%
+23.77K
+0.94%
Jun 30, 2025
Novo Holdings A/S
1.50M
2.99%
+55.00
+0.00%
Jun 30, 2025
Citadel Advisors LLC
1.41M
2.8%
-39.64K
-2.74%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.38M
2.75%
-2.14K
-0.16%
Jun 30, 2025
State Street Investment Management (US)
1.38M
2.74%
-118.94K
-7.96%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Innovator IBD 50 Fund ETF
2.66%
Virtus LifeSci Biotech Products ETF
2.49%
ALPS Medical Breakthroughs ETF
2.17%
Invesco Dorsey Wright Healthcare Momentum ETF
1.66%
Tema Heart & Health ETF
1.32%
First Trust Innovation Leaders ETF
1.17%
Federated Hermes MDT Small Cap Core ETF
1.13%
First Trust Small Cap Growth AlphaDEX Fund
0.8%
SPDR S&P Biotech ETF
0.62%
First Trust NASDAQ Pharmaceuticals ETF
0.5%
查看更多
Innovator IBD 50 Fund ETF
佔比2.66%
Virtus LifeSci Biotech Products ETF
佔比2.49%
ALPS Medical Breakthroughs ETF
佔比2.17%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.66%
Tema Heart & Health ETF
佔比1.32%
First Trust Innovation Leaders ETF
佔比1.17%
Federated Hermes MDT Small Cap Core ETF
佔比1.13%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.8%
SPDR S&P Biotech ETF
佔比0.62%
First Trust NASDAQ Pharmaceuticals ETF
佔比0.5%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
